medigraphic.com
Boletín Médico del Hospital Infantil de México

2012, Number 1

<< Back Next >>

Bol Med Hosp Infant Mex 2012; 69 (1)

Estimation of chemotherapy costs applying the full protocol of children with acute lymphoblastic leukemia or Hodgkin's lymphoma: case study

Jasso-Gutiérrez L, Dorantes AE, Rodríguez OEE, Pasillas-Torres EM, Muñoz HO

Language: Spanish
References: 27
Page: 11-23
PDF size: 324.82 Kb.


ABSTRACT

Introduction. Of all types of cancer, acute lymphoblastic leukemia (ALL) constitutes the most common type of cancer during the pediatric age. Lymphomas occupy third place. Treatment costs of ALL and Hodgkin lymphoma (HL) in children are high. The aim of the study was to calculate total unit costs of drugs in cancer children with ALL and HL using the current protocols in the Hospital Infantil de Mexico Federico Gomez (HIMFG). The costs were estimated by risk stratification for ALL patients and according to tumor stage for HL.
Methods. Calculations were performed using a specific methodology and using the complete protocols of ALL and HL in the different strata for a child weighing 20 kg with a height of 115 cm and 30 kg with a height of 135 cm.
Results. The total unit cost in standard-risk ALL was 71,655.00 MXN (~$5,430 USD at the time of publication) in the patient weighing 20 kg and 95,825.90 MXN (~$7,250 USD) for the patient weighing 30 kg. In HL, the cost of stage IB-IIB was 39,342.16 MXN (~$3,000 USD) in the child weighing 20 kg and 52,620.14 MXN (~$4,000 USD) in the child weighing 30 kg. Costs for treating patient in stages III-IV corresponded to 41,469.46 MXN (~$3,150 USD) and 55,465.39 MXN (~$4,200.00), respectively.
Conclusions. There were both differences and advantages in the HIMFG protocol for ALL. Comparing costs with costs in other countries showed similar results when only the unit costs were evaluated.


REFERENCES

  1. INEGI. Estadísticas de mortalidad. Consulta interactiva de datos. Disponible en: http://www.inegi.org.mx/est/contenidos/espanol/proyectos/continuas/vitales/bd/mortalidad/Mortalidad-General.asp

  2. Rivera-Luna R. El Niño con Cáncer. Los Padecimientos más Comunes para el Médico no Especialista. México: Editores de Textos Mexicanos; 2007.

  3. Surveillance, Epidemiology and End Results. SEER Cancer Statistics Review 1973–1998. Bethesda (MD): National Cancer Institute; 1998. Disponible en: http://seer.cancer.gov/csr/1973_1998/

  4. Bleyer WA. The U.S. pediatric cancer clinical trials programmes: international implications and the way forward. Eur J Cancer 1997;33:1439-1447.

  5. Pérez-Saldívar ML, Fajardo-Gutiérrez A, Bernáldez-Ríos R, Martínez-Ávalos A, Medina-Sansón A, Espinosa-Hernández L, et al. Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology. BMC Cancer 2011;11:355.

  6. Krasin MJ, Rai SN, Kun LE, Merchant TE, Metzger ML, Kaste SC, et al. Patterns of treatment failure in pediatric and young adult patients with Hodgkin's disease: local disease control with combined-modality therapy. J Clin Oncol 2005;23:8406-8413.

  7. Jønsson V, Hansen MM, Ljungman P, Kaasa S. Pharmacoeconomic considerations in treating patients with acute leukaemia. Pharmacoeconomics 1999;15:167-178.

  8. Pickard AS, Topfer LA, Feeny DH. A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia. J Natl Cancer Inst Monogr 2004;33:102-125.

  9. Kasteng F, Sobocki P, Svedman C, Lundkvist J. Economic evaluations of leukemia: a review of the literature. Int J Technol Assess Health Care 2007;23:43-53.

  10. Gaynon PS, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Steinherz PG, et al. Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies. J Clin Oncol 2001;19:1916-1925.

  11. Van Litsenburg RR, Uyl-de Groot CA, Raat H, Kaspers GJ, Gemke RJ. Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: the influence of new medication and diagnostic technology. Pediatr Blood Cancer 2011;57:1005-1010.

  12. Molina F, Schramm C, Ruiz G. Direct costs of pharmacotherapy for acute leukemia at a Regional Hospital in Chile. Rev Med Chil 2009;137:1553-1560.

  13. Stefan DC, Stones D. How much does it cost to treat children with Hodgkin lymphoma in Africa? Leuk Lymphoma 2009;50:196-199.

  14. Ruiz-Argüelles GJ, Tarin-Arzaga LC, González-Carrillo ML, Gutiérrez-Riveroll KI, Rangel-Malo R, Gutiérrez-Aguirre CH, et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant 2008;42:23-28.

  15. Rocha-García A, Hernández-Peña P, Ruiz-Velazco S, Ávila- Burgos L, Marín-Palomares T, Lazcano-Ponce E. Out-ofpocket expenditures during hospitalization of young leukemia patients with state medical insurance in two Mexican hospitals. Salud Publica Mex 2003;45:285-292.

  16. Knaul F, Arreola-Ornelas H, Méndez O, Martínez A. Fair health financing and catastrophic health expenditures: potential impact of the coverage extension of the popular health insurance in Mexico. Salud Publica Mex 2005;47(suppl 1):S54-S65.

  17. Diario Oficial de la Federación. Decreto por el que se reforma y adiciona la Ley General de Salud. 15 de mayo de 2003. Disponible en: http://dof.gob.mx/nota_to_imagen_fs.php?codnota=695626&fecha=15/05/2003&cod_diario=28260

  18. Consejo de Salubridad General. Comisión Interinstitucional del Cuadro Básico de Insumos del Sector Salud. Cuadro básico y catálogo de medicamentos; 2010. Disponible en: http://www.csg.salud.gob.mx/descargas/pdfs/cuadro_basico/medicamentos/medicamentos_ed2010.pdf

  19. Jasso-Gutiérrez L, Santos-Preciado JI. Perfil comparativo de medicamentos en el Hospital Infantil de México y el Instituto Mexicano del Seguro Social. Gac Med Mex 2010;146:304-310.

  20. Consejo Nacional para la Prevención y el Tratamiento del Cáncer en la Infancia y Adolescencia. Protocolos Técnicos Cáncer en Niños. México: Editores de Textos Mexicanos; 2010.

  21. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003;101:3809-3817.

  22. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734-745.

  23. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010;24:371-382.

  24. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:7161-7167.

  25. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007;(3):CD005590.

  26. Harrison AM, Lugo RA, Vernon DD. Gastric pH control in critically ill children receiving intravenous ranitidine. Crit Care Med 1998;26:1433-1436.

  27. Lopez-Herce Cid J, Albajara Velasco L, Codoceo R, Delgado-Domínguez MA, Jiménez E, Ruza Tarrio F. Ranitidine prophylaxis in acute gastric mucosal damage in critically ill pediatric patients. Crit Care Med 1988;16:591-593.




2020     |     www.medigraphic.com